CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
如何治疗弥漫性大 B 细胞淋巴瘤：肿瘤学与心血管方面的考量
英文原题：How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations.
查看英文原题
How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
含蒽环类药物的治疗是弥漫性大B细胞淋巴瘤（DLBCL）一线治疗的基石，而自体干细胞移植以及近年来出现的CAR-T 细胞治疗是复发难治性DLBCL的主要治疗选择。鉴于这些治疗均与心血管毒性相关，伴有基础心脏合并症的患者在治疗选择上受到严重限制。本综述的重点是概述这些标准治疗相关的心脏毒性，探讨为减轻这些毒性而开发的策略，并回顾针对伴有基础心血管合并症患者的新型治疗策略。伴有基础心脏并发症的DLBCL患者属于高危人群，需要复杂的管理策略，采用心脏科医生与肿瘤科医生协作的多学科方法。
展开英文摘要原文
Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-cell lymphoma (DLBCL), and autologous stem cell transplantation, and more recently, chimeric antigen receptor T-cell therapy are the primary treatment options for relapsed refractory DLBCL. Given these therapies are all associated with cardiovascular toxicities, patients with underlying cardiac comorbidities are severely limited in treatment options.
The focus of this review is to outline the cardiotoxicities associated with these standard treatments, explore strategies developed to mitigate these toxicities, and review novel treatment strategies for patients with underlying cardiovascular comorbidities. DLBCL patients with underlying cardiac complications are a high-risk patient population who require complicated management strategies that utilize a multidisciplinary approach with collaboration between cardiologists and oncologists.
论文信息
- 作者
- Thiruvengadam SK、Herrera AF、Rhee JW
- 第一作者单位
- Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.United States
- 通讯作者单位
- Department of Cardiology, City of Hope National Medical Center, Duarte, California, USA.United States
- 文献类型
- 综述
- 期刊
- JACC. CardioOncology2023 Jun
- 原文标识
- PubMed 37397077 · DOI 10.1016/j.jaccao.2023.05.001
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →